User profiles for JOHN A. THOMPSON
 | John F ThompsonMelanoma Institute Australia Verified email at melanoma.org.au Cited by 83298 |
[PDF][PDF] Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
…, A Sober, JA Thompson, JF Thompson - Journal of Clinical …, 2001 - jfisher.pbworks.com
Purpose: To revise the staging system for cutaneous melanoma under the auspices of the
American Joint Committee on Cancer (AJCC). Materials and Methods: The prognostic factors …
American Joint Committee on Cancer (AJCC). Materials and Methods: The prognostic factors …
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system
…, SJ Soong, JE Gershenwald, JF Thompson… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: The American Joint Committee on Cancer (AJCC) recently proposed major
revisions of the tumor-node-metastases (TNM) categories and stage groupings for cutaneous …
revisions of the tumor-node-metastases (TNM) categories and stage groupings for cutaneous …
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice …
…, JS Weber, JD Wolchok, JA Thompson… - Journal of clinical …, 2018 - ascopubs.org
Purpose To increase awareness, outline strategies, and offer guidance on the recommended
management of immune-related adverse events in patients treated with immune …
management of immune-related adverse events in patients treated with immune …
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update
…, U Swami, JA Thompson… - Journal of clinical …, 2021 - ingentaconnect.com
PURPOSE To increase awareness, outline strategies, and offer guidance on the recommended
management of immune-related adverse events (irAEs) in patients treated with immune …
management of immune-related adverse events (irAEs) in patients treated with immune …
[HTML][HTML] Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
…, E Solska, G Wilding, JA Thompson… - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
Purpose A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa
(IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic …
(IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic …
Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors
BACKGROUND: A phase 3 trial demonstrated superiority at interim analysis for everolimus
over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on …
over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on …
[HTML][HTML] PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma
…, JC Sunshine, JM Taube, JA Thompson… - … England Journal of …, 2016 - Mass Medical Soc
Background Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to
ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell …
ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell …
[HTML][HTML] Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4),
anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) …
anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) …
[HTML][HTML] Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1
…, A Jungbluth, S Gnjatic, JA Thompson… - … England Journal of …, 2008 - Mass Medical Soc
<p id="p001">We developed an in vitro method for isolating and expanding autologous CD4+
T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused …
T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused …
Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts.
…, JS Beckman, JA Thompson - Proceedings of the …, 1996 - National Acad Sciences
Inflammatory processes in chronic rejection remain a serious clinical problem in organ
transplantation. Activated cellular infiltrate produces high levels of both superoxide and nitric …
transplantation. Activated cellular infiltrate produces high levels of both superoxide and nitric …